Department of Endocrinology and Metabolism, Odense University Hospital, Kløvervænget 6, 5000 Odense C, Denmark.
Eur J Endocrinol. 2011 Oct;165(4):491-7. doi: 10.1530/EJE-11-0299. Epub 2011 Jul 1.
Overt hyperthyroidism has been associated with cardiac arrhythmias, hypercoagulopathy, stroke, and pulmonary embolism, all of which may increase mortality. Some, but not all, studies show an increased mortality in patients with hyperthyroidism. This inconsistency may be due to differences in study design, characteristics of participants, or confounders. In order to test whether hyperthyroidism influences mortality, we performed a critical review and statistical meta-analysis.
Based on an electronic PubMed search, using the Medical Subject Heading words such as hyperthyroidism, thyrotoxicosis, and mortality or survival, case-control and cohort studies were selected and reviewed. Using meta-analysis, an overall relative risk (RR) of mortality was calculated.
Eight studies fulfilled the inclusion criteria, six of which showed an increased all-cause mortality; seven studies, including 31,138 patients and 400,000 person years at risk, allowed calculation of mortality in a meta-analysis. Based on this, the RR of overall mortality was 1.21 (95% confidence interval: 1.05-1.38). Analyses including studies considering setting, treatment, and control for co-morbidity did not significantly alter this finding. As the measured heterogeneity (I(2)) ranges from 89.1 to 98.3%, which is much higher than the 50% generally viewed on as a threshold, the statistical heterogeneity is very pronounced in the included studies.
In patients diagnosed with hyperthyroidism, mortality is increased by ∼ 20%. Future studies need to address the cause of hyperthyroidism, impact of type of therapy, time dependency, as well as the potential influence of confounding or genetic susceptibility before the question of causality can be answered.
显性甲状腺功能亢进症与心律失常、高凝状态、中风和肺栓塞有关,所有这些都可能增加死亡率。一些(但不是全部)研究表明甲状腺功能亢进症患者的死亡率增加。这种不一致可能是由于研究设计、参与者特征或混杂因素的差异。为了检验甲状腺功能亢进症是否影响死亡率,我们进行了批判性评价和统计荟萃分析。
基于电子 PubMed 搜索,使用医学主题词如甲状腺功能亢进症、甲状腺毒症和死亡率或生存率,选择并回顾了病例对照和队列研究。使用荟萃分析,计算了死亡率的总体相对风险(RR)。
八项研究符合纳入标准,其中六项研究显示全因死亡率增加;七项研究(包括 31138 名患者和 400000 人年的风险暴露)允许进行荟萃分析计算死亡率。基于此,总死亡率的 RR 为 1.21(95%置信区间:1.05-1.38)。包括考虑设置、治疗和合并症控制的研究的分析并没有显著改变这一发现。由于测量的异质性(I(2))范围为 89.1%至 98.3%,远高于通常认为的 50%阈值,因此纳入研究的统计学异质性非常显著。
在诊断为甲状腺功能亢进症的患者中,死亡率增加了约 20%。未来的研究需要解决甲状腺功能亢进症的病因、治疗类型的影响、时间依赖性以及混杂因素或遗传易感性的潜在影响,然后才能回答因果关系的问题。